JP2000513720A - 修飾された第vii因子 - Google Patents
修飾された第vii因子Info
- Publication number
- JP2000513720A JP2000513720A JP10501082A JP50108298A JP2000513720A JP 2000513720 A JP2000513720 A JP 2000513720A JP 10501082 A JP10501082 A JP 10501082A JP 50108298 A JP50108298 A JP 50108298A JP 2000513720 A JP2000513720 A JP 2000513720A
- Authority
- JP
- Japan
- Prior art keywords
- factor
- factor vii
- phe
- dansyl
- protease inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.患者における血栓形成を阻害するための方法であって、血漿第X又はIX因 子を活性化する修飾された第VII因子の能力を実質的に阻害する少なくとも1つ の修飾をその触媒中心に有する第VII因子を含んで成る治療的有効用量の組成物 を、前記患者における血栓形成に対して敏感な血管部位に局部投与することを含 んで成る方法。 2.前記修飾がセリンプロテアーゼインヒビターとVII因子との反応を含んで 成る請求の範囲第1項記載の方法。 3.前記プロテアーゼインヒビターが、有機リン化合物、スルファニルフルオ リド、ペプチドハロメチルケトン、又はアザペプチドである請求の範囲第2項記 載の方法。 4.前記プロテアーゼインヒビターが、ダンシル-Phe-Pro-Argクロロメチルケ トン、ダンシル-Glu-Gly-Argクロロメチルケトン、ダンシル-Phe-Phe-Argクロロ メチルケトン及びPhe-Phe-Argクロロメチルケトンから選択されたペプチドハロ メチルケトンである請求の範囲第3項記載の方法。 5.前記血栓形成の部位が手術、顕微手術、血管形成又は外傷に関連している 請求の範囲第1〜4のいづれか1項記載の方法。 6.患者における血管開通性を維持し、又は改良するための方法であって、血 漿第X又はIX因子を活性化する修飾された第VII因子の能力を実質的に阻害する 少なくとも1つの修飾をその触媒中心に有する第VII因子を含んで成る治療的有 効用量の組成物を、低められた開通性に対して敏感な血管部位に局部投与するこ とを含んで成る方法。 7.前記修飾がセリンプロテアーゼインヒビターと第VII因子との反応を含ん で成る請求の範囲第6項記載の方法。 8.前記プロテアーゼインヒビターが、有機リン化合物、スルファニルフルオ リド、ペプチドハロメチルケトン、又はアザペプチドである請求の範囲第7項記 載の方法。 9.前記プロテアーゼインヒビターが、ダンシル-Phe-Pro-Argクロロメチルケ トン、ダンシル-Glu-Gly-Argクロロメチルケトン、ダンシル-Phe-Phe-Argクロロ メチルケトン及びPhe-Phe-Argクロロメチルケトンから選択されたペプチドハロ メチルケトンである請求の範囲第8項記載の方法。 10.前記低められた開通性の部位が手術、顕微手術、血管形成又は外傷に関連 している請求の範囲第6〜9のいづれか1項記載の方法。 11.後−虚血性再灌流に関連する心筋損傷を妨げ又は最小にするための組成物 の製造のためへの、血漿第X又はIX因子を活性化する修飾された第VII因子の能 力を実質的に阻害する少なくとも1つの修飾をその触媒中心に有する第VII因子 の使用。 12.前記修飾がセリンプロテアーゼインヒビターと第VII因子との反応を含ん で成る請求の範囲第16項記載の使用。 13.前記プロテアーゼインヒビターが、有機リン化合物、スルファニルフルオ リド、ペプチドハロメチルケトン、又はアザペプチドである請求の範囲第17項記 載の使用。 14.前記プロテアーゼインヒビターが、ダンシル-Phe-Pro-Argクロロメチルケ トン、ダンシル-Glu-Gly-Argクロロメチルケトン、ダンシル-Phe-Phe-Argクロロ メチルケトン及びPhe-Phe-Argクロロメチルケトンから選択されたペプチドハロ メチルケトンである請求の範囲第18項記載の使用。 15.前記心筋損傷が、心筋壊死である請求の範囲第16〜19のいづれか1項記載 の使用。 16.個人における後−虚血性再灌流に関連する心筋損傷を妨げ又は最小にする ための方法であって、血漿第X又はIX因子を活性化する修飾された第VII因子の 能力を実質的に阻害する少なくとも1つの修飾をその触媒中心に有する薬理学的 に許容できる第VII因子を含んで成る組成物を前記個人に投与することを含んで 成る方法。 17.前記修飾がセリンプロテアーゼインヒビターと第VII因子との反応を含ん で成る請求の範囲第21項記載の方法。 18.前記プロテアーゼインヒビターが、有機リン化合物、スルファニルフルオ リド、ペプチドハロメチルケトン、又はアザペプチドである請求の範囲第22項記 載の方法。 19.前記プロテアーゼインヒビターが、ダンシル-Phe-Pro-Argクロロメチルケ トン、ダンシル-Glu-Gly-Argクロロメチルケトン、ダンシル-Phe-Phe-Argクロロ メチルケトン及びPhe-Phe-Argクロロメチルケトンから選択されたペプチドハロ メチルケトンである請求の範囲第23項記載の方法。 20.前記心筋損傷が心筋壊死である請求の範囲第21〜24のいづれか1項記載の 方法。 21.後−虚血性再灌流の間、局部心筋血流を改良するための組成物の製造のた めへの、血漿第X又はIX因子を活性化する修飾された第VII因子の能力を実質的 に阻害する少なくとも1つの修飾をその触媒中心に有する第VII因子の使用。 22.前記修飾がセリンプロテアーゼインヒビターと第VII因子との反応を含ん で成る請求の範囲第26項記載の使用。 23.前記プロテアーゼインヒビターが、有機リン化合物、スルファニルフルオ リド、ペプチドハロメチルケトン、又はアザペプチドである請求の範囲第27項記 載の使用。 24.前記プロテアーゼインヒビターが、ダンシル-Phe-Pro-Argク ロロメチルケトン、ダンシル-Glu-Gly-Argクロロメチルケトン、ダンシル-Phe-P he-Argクロロメチルケトン及びPhe-Phe-Argクロロメチルケトンから選択された ペプチドハロメチルケトンである請求の範囲第28項記載の使用。 25.個人における後−虚血性再灌流の間、局部心筋血流を改良するための方法 であって、血漿第X又はIX因子を活性化する修飾された第VII因子の能力を実質 的に阻害する少なくとも1つの修飾をその触媒中心に有する薬理学的に許容でき る第VII因子を含んで成る組成物を前記個人に投与することを含んで成る方法。 26.前記修飾がセリンプロテアーゼインヒビターと第VII因子との反応を含ん で成る請求の範囲第30項記載の方法。 27.前記プロテアーゼインヒビターが、有機リン化合物、スルファニルフルオ リド、ペプチドハロメチルケトン、又はアザペプチドである請求の範囲第31項記 載の方法。 28.前記プロテアーゼインヒビターが、ダンシル-Phe-Pro-Argクロロメチルケ トン、ダンシル-Glu-Gly-Argクロロメチルケトン、ダンシル-Phe-Phe-Argクロロ メチルケトン及びPhe-Phe-Argクロロメチルケトンから選択されたペプチドハロ メチルケトンである請求の範囲第32項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/660,289 US5833982A (en) | 1991-02-28 | 1996-06-07 | Modified factor VII |
US08/660,289 | 1996-06-07 | ||
PCT/DK1997/000251 WO1997047651A1 (en) | 1996-06-07 | 1997-06-06 | Modified factor vii |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000513720A true JP2000513720A (ja) | 2000-10-17 |
JP2000513720A5 JP2000513720A5 (ja) | 2005-03-10 |
Family
ID=24648892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10501082A Ceased JP2000513720A (ja) | 1996-06-07 | 1997-06-06 | 修飾された第vii因子 |
Country Status (17)
Country | Link |
---|---|
US (2) | US5833982A (ja) |
EP (1) | EP0910580A1 (ja) |
JP (1) | JP2000513720A (ja) |
KR (1) | KR20000016415A (ja) |
CN (2) | CN1131872C (ja) |
AU (1) | AU735012B2 (ja) |
BR (1) | BR9709661A (ja) |
CA (1) | CA2256761A1 (ja) |
CZ (1) | CZ394698A3 (ja) |
HU (1) | HUP0003077A3 (ja) |
IL (1) | IL127099A0 (ja) |
NO (1) | NO985668L (ja) |
PL (1) | PL330365A1 (ja) |
RU (1) | RU2211704C2 (ja) |
UA (1) | UA68333C2 (ja) |
WO (1) | WO1997047651A1 (ja) |
ZA (1) | ZA975013B (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005530752A (ja) * | 2002-05-03 | 2005-10-13 | ノボ ノルディスク アクティーゼルスカブ | 修飾第vii因子の安定化された固体組成物 |
JP2008514677A (ja) * | 2004-09-29 | 2008-05-08 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 陰イオン交換物質からの分画溶出によるvii因子ポリペプチドのバルクの精製 |
US7790852B2 (en) | 2003-06-25 | 2010-09-07 | Novo Nordisk Health Care A/G | Liquid composition of factor VII polypeptides |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US8022031B2 (en) | 2001-12-21 | 2011-09-20 | Novo Nordisk Health Care A/G | Liquid composition of factor VII polypeptides |
US8026214B2 (en) | 2003-08-14 | 2011-09-27 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides |
US8299029B2 (en) | 2002-06-21 | 2012-10-30 | Novo Nordisk Health Care Ag | Stabilised solid compositions of factor VII polypeptides |
US8536127B2 (en) | 2003-05-23 | 2013-09-17 | Novo Nordisk Healthcare Ag | Protein stabilization in solution |
US8658597B2 (en) | 2003-12-19 | 2014-02-25 | Novo Nordisk Healthcare Ag | Stabilised compositions of factor VII polypeptides |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
US20040087498A1 (en) * | 1991-02-28 | 2004-05-06 | Novo Nordisk Health Care Ag | Modified factor VII |
EP1005361B1 (en) * | 1997-07-18 | 2010-01-06 | Novo Nordisk Health Care AG | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6406488B1 (en) * | 1998-08-27 | 2002-06-18 | Heartstent Corporation | Healing transmyocardial implant |
EP0987274A1 (en) | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
EP1059302A1 (en) | 1999-06-08 | 2000-12-13 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitors |
US6924359B1 (en) * | 1999-07-01 | 2005-08-02 | Yale University | Neovascular-targeted immunoconjugates |
EP1095933A1 (en) | 1999-10-30 | 2001-05-02 | Aventis Pharma Deutschland GmbH | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
RU2278123C2 (ru) * | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
AU2001259063A1 (en) * | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7812132B2 (en) * | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
EP1162194A1 (en) | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
WO2001097752A2 (en) * | 2000-06-20 | 2001-12-27 | The Trustees Of The University Of Pennsylvania | Compositions comprising urokinase for modulating muscle contractility and angiogenisis |
US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
RU2003120070A (ru) | 2000-12-06 | 2004-12-27 | Авентис Фармаа Дойчланд Гмбх (De) | Производные гуанидина и амидина в качестве ингибиторов фактора ха |
US6825323B2 (en) * | 2001-01-10 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same |
US7235638B2 (en) | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
AU2002249096B2 (en) * | 2001-03-22 | 2007-06-28 | Novo Nordisk Health Care Ag | Coagulation factor VII derivatives |
PL366564A1 (en) * | 2001-05-02 | 2005-02-07 | Novo Nordisk A/S | Modified fvii in treatment of ards |
EP1270551A1 (en) | 2001-06-26 | 2003-01-02 | Aventis Pharma Deutschland GmbH | Urea derivatives with antiproteolytic activity |
AU2002326135A1 (en) * | 2001-09-10 | 2003-03-24 | Florence Medical Ltd. | Individual ffr determination for lesions of a multi-lesioned blood vessel |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
CN105131104B (zh) | 2001-10-10 | 2018-11-16 | 诺和诺德公司 | 肽的重构和糖缀合 |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
AU2002336920A1 (en) * | 2001-11-02 | 2003-05-12 | Novo Nordisk Health Care Ag | Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
RU2004122430A (ru) * | 2001-12-21 | 2005-04-20 | Ново Нордиск А/С (DK) | Жидкая композиция полипептидов модифицированного фактора vii |
SI1499719T1 (sl) * | 2002-04-30 | 2011-03-31 | Bayer Healthcare Llc | Polipeptidne variante faktorja VII ali VIIa |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
US20060166874A1 (en) * | 2002-09-30 | 2006-07-27 | Haaning Jesper M | Fvii or fviia variants having increased clotting activity |
US7358268B2 (en) | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
WO2004082708A2 (en) * | 2003-03-18 | 2004-09-30 | Novo Nordisk Health Care Ag | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
DK2085470T3 (da) * | 2003-03-20 | 2012-08-06 | Bayer Healthcare Llc | FVII- eller FVIIa-varianter |
EP2338333B1 (en) | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Glycopegylation methods and proteins/peptides produced by the methods |
US20040202726A1 (en) * | 2003-04-10 | 2004-10-14 | Deshay Samuel L. | Topical blood pressure composition |
US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
EP1479677A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
EP1479680A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Azaindole derivatives as Factor Xa inhibitors |
EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
US7029675B1 (en) * | 2003-06-04 | 2006-04-18 | Shu-Wha Lin | Hepsin antagonist and methods of use |
CN1839203B (zh) * | 2003-06-19 | 2011-11-16 | 拜耳医药保健有限公司 | 因子VII或VIIa的GLA结构域变体 |
DE602004023848D1 (de) * | 2003-07-01 | 2009-12-10 | Novo Nordisk Healthcare Ag | Von factor vii polypeptiden |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
SI2586456T1 (sl) | 2004-10-29 | 2016-05-31 | Ratiopharm Gmbh | Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF) |
EP1858543B1 (en) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
ES2406267T3 (es) | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Métodos de tratamiento usando G-CSF glicopegilado |
WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
BR122021014783B1 (pt) | 2008-12-19 | 2023-03-14 | Baxalta GmbH | Peptídeo que se liga a tfpi, uso do peptídeo, composição farmacêutica e método para purificação de tfpi |
AU2010290077C1 (en) | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
CN103025345B (zh) | 2010-03-19 | 2016-01-20 | 巴克斯特国际公司 | Tfpi抑制剂及使用方法 |
KR101294351B1 (ko) * | 2010-05-27 | 2013-08-07 | 동국대학교 산학협력단 | 뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법 |
ES2771208T3 (es) | 2012-02-15 | 2020-07-06 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
EP3549953A1 (en) | 2012-02-15 | 2019-10-09 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
AU2013235741C1 (en) | 2012-03-21 | 2017-12-21 | Takeda Pharmaceutical Company Limited | TFPI inhibitors and methods of use |
WO2015023891A2 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Factor viii-xten fusions and uses thereof |
CA2990837A1 (en) * | 2015-07-22 | 2017-01-26 | Iconic Therapeutics, Inc. | Methods for treating disorders associated with angiogenesis and neovascularization |
EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
AU2017206445B2 (en) | 2016-01-15 | 2019-07-18 | Rigshospitalet | Quantitative pet imaging of tissue factor expression using 18F-labled active site inhibited factor VII |
WO2018091058A1 (en) | 2016-11-17 | 2018-05-24 | Rigshospitalet | 177-lu labeled active site inhibited factor vii |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US4770999A (en) * | 1985-04-22 | 1988-09-13 | Genetics Institute, Inc. | High yield production of active Factor IX |
US4959318A (en) * | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
US4829052A (en) * | 1986-06-11 | 1989-05-09 | Monsanto Company | Serine protease inhibitors |
US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
EP0278727A3 (en) | 1987-02-10 | 1990-03-14 | Glaxo Group Limited | 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-(substituted amino)ethanol derivatives and their use in the treatment of respiratory disease |
FR2619314B1 (fr) * | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US4994371A (en) * | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
US5023236A (en) * | 1988-04-07 | 1991-06-11 | Corvas, Inc. | Factor VII/VIIA active site inhibitors |
US5258180A (en) * | 1988-09-02 | 1993-11-02 | Genetech, Inc. | Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment |
AU4338689A (en) * | 1988-09-23 | 1990-04-18 | Corvas, Inc. | Peptidyl inhibitors of the initiation of coagulation |
US5120537A (en) * | 1989-06-14 | 1992-06-09 | Oklahoma Medical Research Foundation | Factor xa based anticoagulant compositions |
US5190919A (en) * | 1989-11-13 | 1993-03-02 | Board Of Regents, The University Of Texas System | Antihemostatic factor vii peptides |
ATE180834T1 (de) | 1990-01-29 | 1999-06-15 | Zymogenetics Inc | Antikoagulierende proteine |
US5278144A (en) * | 1990-09-04 | 1994-01-11 | Cor Therapeutics, Inc. | Antithrombosis agents |
US5817788A (en) | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
US5861374A (en) | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
JP3459416B2 (ja) * | 1991-02-28 | 2003-10-20 | ザイモジェネティクス,インコーポレイティド | 修飾されたファクター▲vii▼ |
US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
US5326559A (en) * | 1991-05-16 | 1994-07-05 | Miller D Douglas | Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules |
US5419760A (en) * | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
GB9301093D0 (en) * | 1993-01-20 | 1993-03-10 | Rca Thomson Licensing Corp | Digital video tape recorder for digital hdtv |
HU219682B (hu) * | 1993-05-21 | 2001-06-28 | Novo Nordisk A/S. | Módosított VII faktor |
US5648331A (en) * | 1994-08-26 | 1997-07-15 | G.D. Searle & Co. | Method of inhibiting tissue ischemia and reperfusion injury |
-
1996
- 1996-06-07 US US08/660,289 patent/US5833982A/en not_active Expired - Fee Related
-
1997
- 1997-06-06 JP JP10501082A patent/JP2000513720A/ja not_active Ceased
- 1997-06-06 CN CN97195294A patent/CN1131872C/zh not_active Expired - Fee Related
- 1997-06-06 PL PL97330365A patent/PL330365A1/xx unknown
- 1997-06-06 BR BR9709661-0A patent/BR9709661A/pt not_active IP Right Cessation
- 1997-06-06 WO PCT/DK1997/000251 patent/WO1997047651A1/en not_active Application Discontinuation
- 1997-06-06 CA CA002256761A patent/CA2256761A1/en not_active Abandoned
- 1997-06-06 HU HU0003077A patent/HUP0003077A3/hu unknown
- 1997-06-06 CZ CZ983946A patent/CZ394698A3/cs unknown
- 1997-06-06 EP EP97925917A patent/EP0910580A1/en not_active Withdrawn
- 1997-06-06 UA UA98126442A patent/UA68333C2/uk unknown
- 1997-06-06 CN CNA031066089A patent/CN1515318A/zh active Pending
- 1997-06-06 KR KR1019980709998A patent/KR20000016415A/ko not_active Application Discontinuation
- 1997-06-06 AU AU30906/97A patent/AU735012B2/en not_active Ceased
- 1997-06-06 IL IL12709997A patent/IL127099A0/xx unknown
- 1997-06-06 ZA ZA9705013A patent/ZA975013B/xx unknown
- 1997-06-06 RU RU99100089/14A patent/RU2211704C2/ru not_active IP Right Cessation
-
1998
- 1998-11-10 US US09/189,607 patent/US6168789B1/en not_active Expired - Fee Related
- 1998-12-04 NO NO985668A patent/NO985668L/no not_active Application Discontinuation
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8461116B2 (en) | 2001-12-21 | 2013-06-11 | Novo Nordisk Healthcare Ag | Liquid composition of factor VII polypeptides |
US8022031B2 (en) | 2001-12-21 | 2011-09-20 | Novo Nordisk Health Care A/G | Liquid composition of factor VII polypeptides |
JP2005530752A (ja) * | 2002-05-03 | 2005-10-13 | ノボ ノルディスク アクティーゼルスカブ | 修飾第vii因子の安定化された固体組成物 |
US8729022B2 (en) | 2002-06-21 | 2014-05-20 | Novo Nordisk Healthcare Ag | Stabilised solid compositions of factor VII polypeptides |
US8299029B2 (en) | 2002-06-21 | 2012-10-30 | Novo Nordisk Health Care Ag | Stabilised solid compositions of factor VII polypeptides |
US8084587B2 (en) | 2003-03-26 | 2011-12-27 | Novo Nordisk Health Care Ag | Method for the production of proteins |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US8536127B2 (en) | 2003-05-23 | 2013-09-17 | Novo Nordisk Healthcare Ag | Protein stabilization in solution |
US7790852B2 (en) | 2003-06-25 | 2010-09-07 | Novo Nordisk Health Care A/G | Liquid composition of factor VII polypeptides |
US8026214B2 (en) | 2003-08-14 | 2011-09-27 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides |
US8318904B2 (en) | 2003-08-14 | 2012-11-27 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides |
US8658597B2 (en) | 2003-12-19 | 2014-02-25 | Novo Nordisk Healthcare Ag | Stabilised compositions of factor VII polypeptides |
JP2013056891A (ja) * | 2004-09-29 | 2013-03-28 | Novo Nordisk Health Care Ag | 陰イオン交換物質からの分画溶出によるvii因子ポリペプチドのバルクの精製 |
JP2008514677A (ja) * | 2004-09-29 | 2008-05-08 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 陰イオン交換物質からの分画溶出によるvii因子ポリペプチドのバルクの精製 |
JP2016006074A (ja) * | 2004-09-29 | 2016-01-14 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 陰イオン交換物質からの分画溶出によるvii因子ポリペプチドのバルクの精製 |
Also Published As
Publication number | Publication date |
---|---|
RU2211704C2 (ru) | 2003-09-10 |
CA2256761A1 (en) | 1997-12-18 |
AU3090697A (en) | 1998-01-07 |
IL127099A0 (en) | 1999-09-22 |
NO985668D0 (no) | 1998-12-04 |
AU735012B2 (en) | 2001-06-28 |
US6168789B1 (en) | 2001-01-02 |
PL330365A1 (en) | 1999-05-10 |
EP0910580A1 (en) | 1999-04-28 |
HUP0003077A3 (en) | 2003-01-28 |
ZA975013B (en) | 1997-12-08 |
BR9709661A (pt) | 2000-04-25 |
CN1515318A (zh) | 2004-07-28 |
CZ394698A3 (cs) | 1999-04-14 |
KR20000016415A (ko) | 2000-03-25 |
NO985668L (no) | 1999-02-04 |
CN1221427A (zh) | 1999-06-30 |
HUP0003077A2 (hu) | 2000-12-28 |
US5833982A (en) | 1998-11-10 |
CN1131872C (zh) | 2003-12-24 |
WO1997047651A1 (en) | 1997-12-18 |
UA68333C2 (en) | 2004-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000513720A (ja) | 修飾された第vii因子 | |
US5788965A (en) | Modified factor VII | |
US5817788A (en) | Modified factor VII | |
US6183743B1 (en) | Modified factor VII | |
US5861374A (en) | Modified Factor VII | |
MXPA97002951A (en) | Factor vii modific | |
AU703110B2 (en) | Modified factor VII | |
JP4361728B2 (ja) | ヒト凝固因子vii変異型 | |
JP4456165B2 (ja) | ヒト第vii凝固因子変異型 | |
KR100882482B1 (ko) | 사람 응고 인자 vii 변이체 | |
UA82177C2 (uk) | Поліпептиди фактора коагуляції vii людини | |
US6039944A (en) | Modified Factor VII | |
US20040087498A1 (en) | Modified factor VII | |
Stern et al. | Endothelium and the regulation of coagulation | |
AU766827B2 (en) | Modified factor VII | |
AU5940799A (en) | Modified factor VII | |
MXPA98010211A (en) | Factor vii modific | |
AU2004200261A8 (en) | Modified Factor VII | |
UA48149C2 (uk) | Спосіб інгібування активності фактора тканини, спосіб пригнічення відкладення тромбоцитів, спосіб пригнічення судинного рестенозу, спосіб лікування гострої закупорки коронарної артерії за допомогою модифікованого фактора vii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040622 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080318 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080812 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080930 |